These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15540063)

  • 1. New hope for patients with pulmonary hypertension: endothelin receptor antagonists: update for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2004; 18(5):232-4. PubMed ID: 15540063
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
    Ghofrani HA
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S177-8. PubMed ID: 19718611
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Updated treatment of primary pulmonary hypertension -- the role of endothelin receptor antagonists].
    Callejas Rubio JL; Ortego Centeno N; Navarro Pelayo F; Vallejo Rodríguez I
    Farm Hosp; 2004; 28(4):294-5. PubMed ID: 15369441
    [No Abstract]   [Full Text] [Related]  

  • 5. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
    Mucke HA
    IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan].
    Avdeev SN
    Ter Arkh; 2015; 87(9):64-71. PubMed ID: 26591555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
    Wilkins MR
    Am J Respir Crit Care Med; 2004 Feb; 169(4):433-4. PubMed ID: 14766656
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
    Opitz CF; Ewert R; Kirch W; Pittrow D
    Eur Heart J; 2008 Aug; 29(16):1936-48. PubMed ID: 18562303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
    Kim NH; Rubin LJ
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):9-19. PubMed ID: 12000973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary hypertension in older children: new approaches and therapies.
    Abman SH
    Paediatr Respir Rev; 2006; 7 Suppl 1():S177-9. PubMed ID: 16798555
    [No Abstract]   [Full Text] [Related]  

  • 12. Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
    Luo N; Ryan JJ
    Can J Cardiol; 2013 Jun; 29(6):659-61. PubMed ID: 22985784
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
    Faruqi S; Fathi H; Morice AH
    Int J Cardiol; 2010 Oct; 144(3):e43-5. PubMed ID: 19171388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Langleben D
    Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK; Preston IR
    Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
    Langleben D; Cacoub P
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N; Derk CT
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
    J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
    Montani D; Humbert M
    Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
    [No Abstract]   [Full Text] [Related]  

  • 20. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
    Price LC; Howard LS
    Am J Cardiovasc Drugs; 2008; 8(3):171-85. PubMed ID: 18533738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.